Payment overview · 2025
General Payments
$317.61
12 reported records · 4 companies
Healthcare provider profile · identity verified
Victor E Lambert, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MANCHESTER, GA · NPI 1154317790
Verified facts
What the public records show
CMS Open Payments records show Victor E Lambert, M.D. received $317.61 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 59.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 838 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $189.46 | 59.6% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.53 | 18.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.87 | 16.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.75 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $317.61 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $123.66 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.80 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.80 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $57.53 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.87 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.87 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 838 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
838 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1970 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1856 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1480 | 97 |
| Memantine Hcl | Memantine Hcl | 1172 | 43 |
| Famotidine | Famotidine | 1099 | 64 |
| Furosemide | Furosemide | 1081 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1051 | 61 |
| Omeprazole | Omeprazole | 982 | 75 |
| Potassium Chloride | Potassium Chloride | 960 | 72 |
| Eliquis | Apixaban | 838 | 51 |
| Sertraline Hcl | Sertraline Hcl | 837 | 51 |
| Lisinopril | Lisinopril | 831 | 101 |
| Donepezil Hcl | Donepezil Hcl | 800 | 28 |
| Carvedilol | Carvedilol | 798 | 62 |
| Trazodone Hcl | Trazodone Hcl | 713 | 35 |
| Gabapentin | Gabapentin | 646 | 61 |
| Divalproex Sodium | Divalproex Sodium | 605 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 540 | 35 |
| Metformin Hcl | Metformin Hcl | 537 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 530 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 526 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 504 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 504 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 487 | 30 |
| Losartan Potassium | Losartan Potassium | 480 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 443 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 440 | 24 |
| Mirtazapine | Mirtazapine | 346 | 14 |
| Simvastatin | Simvastatin | 322 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 307 | 47 |
| Levetiracetam | Levetiracetam | 301 | 11 |
| Montelukast Sodium | Montelukast Sodium | 296 | 19 |
| Risperidone | Risperidone | 286 | suppressed |
| Allopurinol | Allopurinol | 259 | 35 |
| Amiodarone Hcl | Amiodarone Hcl | 258 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 258 | 37 |
| Sucralfate | Sucralfate | 249 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 245 | 13 |
| Haloperidol | Haloperidol | 242 | suppressed |
| Meloxicam | Meloxicam | 225 | 42 |
| Alprazolam | Alprazolam | 217 | 45 |
| Olanzapine | Olanzapine | 202 | suppressed |
| Nifedipine Er | Nifedipine | 201 | 24 |
| Xarelto | Rivaroxaban | 197 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 190 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 186 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 185 | 57 |
| Glipizide | Glipizide | 176 | 15 |
| Finasteride | Finasteride | 173 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 168 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 166 | suppressed |
| Atenolol | Atenolol | 165 | 21 |
| Ezetimibe | Ezetimibe | 157 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 143 | 33 |
| Hydrocortisone | Hydrocortisone | 138 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 135 | 16 |
| Benazepril Hcl | Benazepril Hcl | 133 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 131 | suppressed |
| Spironolactone | Spironolactone | 130 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 128 | 12 |
| Bupropion Xl | Bupropion Hcl | 126 | suppressed |
| Januvia | Sitagliptin Phosphate | 125 | suppressed |
| Aripiprazole | Aripiprazole | 124 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 122 | suppressed |
| Fluconazole | Fluconazole | 121 | 34 |
| Meclizine Hcl | Meclizine Hcl | 121 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 120 | 51 |
| Entresto | Sacubitril/Valsartan | 119 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 119 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 116 | suppressed |
| Lamotrigine | Lamotrigine | 113 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 107 | 85 |
| Terazosin Hcl | Terazosin Hcl | 105 | suppressed |
| Methocarbamol | Methocarbamol | 104 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 30 |
| Midodrine Hcl | Midodrine Hcl | 102 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 98 | suppressed |
| Ibuprofen | Ibuprofen | 98 | 16 |
| Bumetanide | Bumetanide | 95 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 92 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 91 | suppressed |
| Clonazepam | Clonazepam | 91 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 87 | suppressed |
| Jardiance | Empagliflozin | 86 | 13 |
| Propranolol Hcl | Propranolol Hcl | 85 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 82 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 80 | 30 |
| Prednisone | Prednisone | 80 | 55 |
| Levemir | Insulin Detemir | 75 | 17 |
| Torsemide | Torsemide | 73 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 72 | suppressed |
| Ramipril | Ramipril | 71 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 69 | 58 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 12 |
| Ziprasidone Hcl | Ziprasidone Hcl | 68 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 67 | 16 |
| Glipizide Er | Glipizide | 64 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 64 | suppressed |
| Tradjenta | Linagliptin | 63 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | suppressed |
| Valsartan | Valsartan | 62 | suppressed |
| Acarbose | Acarbose | 61 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 61 | suppressed |
| Ranolazine Er | Ranolazine | 59 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 13 |
| Cephalexin | Cephalexin | 55 | 48 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 55 | suppressed |
| Ozempic | Semaglutide | 55 | suppressed |
| Baclofen | Baclofen | 53 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 53 | suppressed |
| Glimepiride | Glimepiride | 53 | 11 |
| Lorazepam | Lorazepam | 53 | 12 |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Azithromycin | Azithromycin | 52 | 46 |
| Colesevelam Hcl | Colesevelam Hcl | 52 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 52 | suppressed |
| Metaxalone | Metaxalone | 52 | suppressed |
| Primidone | Primidone | 52 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 52 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 51 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 51 | suppressed |
| Ursodiol | Ursodiol | 51 | suppressed |
| Colchicine | Colchicine | 50 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 50 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Latanoprost | Latanoprost | 48 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 47 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | suppressed |
| Ondansetron Odt | Ondansetron | 45 | 24 |
| Temazepam | Temazepam | 44 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 31 |
| Linzess | Linaclotide | 42 | 16 |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 41 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 14 |
| Amoxicillin | Amoxicillin | 39 | 33 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | suppressed |
| Cefdinir | Cefdinir | 38 | 33 |
| Memantine Hcl Er | Memantine Hcl | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Novolin R | Insulin Regular, Human | 37 | suppressed |
| Novolog | Insulin Aspart | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 24 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 34 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Ceftriaxone | Ceftriaxone Sodium | 30 | 23 |
| Humulin R | Insulin Regular, Human | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Pentoxifylline | Pentoxifylline | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | 11 |
| Renvela | Sevelamer Carbonate | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Exemestane | Exemestane | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 21 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Admelog | Insulin Lispro | 22 | 11 |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 22 | 15 |
| Naproxen | Naproxen | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 16 |
| Lidocaine Hcl | Lidocaine Hcl | 20 | 17 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 19 | 19 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Tresiba | Insulin Degludec | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Austedo Xr | Deutetrabenazine | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Trueplus Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Clonidine | Clonidine | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $317.61 · 12 records | Novo Nordisk Inc | ELIQUIS, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error